Pyrrolidine, 3-(Phenylmethoxy)-, (3S)-, Hydrochloride (1:1)

Removal of the hydrochloride counterion prior to palladium-mediated cross-coupling constitutes the gateway operation for incorporating the (3S)-3-benzyloxypyrrolidine fragment into D3/D2 receptor antagonist scaffolds. On production scale, the white crystalline salt is charged to a nitrogen-inerted Hastelloy C-22 reactor and partitioned between 2.0 M aqueous sodium hydroxide and methyl tert-butyl ether (MTBE) at a 1:1.2 w/w ratio. The free base is extracted at 20–25 °C with rigorous agitation at 300–400 rpm to avoid emulsion formation, then dried over anhydrous sodium sulfate until the moisture content falls below 500 ppm as measured by Karl Fischer coulometric titration (USP <921>, Method Ic). Failure to reduce chloride ion below 50 ppm in the organic phase leads to poisoning of the Pd(0) catalyst in the subsequent C–N bond formation, raising the required catalyst loading beyond 2.0 mol% and reducing turnover numbers below an economically viable 5000.

The Buchwald-Hartwig amination has been optimized using aryl bromides (1.05 eq), Pd(OAc)₂ (0.5–1.0 mol%), and racemic BINAP (1.0–2.0 mol%) in degassed toluene (10 volumes) at 90–95 °C under a nitrogen blanket. Sodium tert-butoxide (1.3–1.5 eq) acts as the base, and the reaction endpoint is confirmed when the residual (S)-3-benzyloxypyrrolidine peak area drops below 0.5% by HPLC (C18 column, acetonitrile/0.1% TFA gradient). Critical to enantiomeric integrity is the exclusion of oxygen and moisture; even 0.1 vol% of adventitious water has been correlated with protonolysis of the Pd–amide intermediate, triggering β-hydride elimination and generating the des-benzyloxy pyrroline impurity at levels up to 3.0% area. Post-reaction, the mixture is cooled to 25 °C, filtered through a compressed pad of acid-washed Celite to reduce palladium content below 20 ppm, and concentrated under vacuum. A solvent swap into isopropanol followed by slow crystallization at −5 to 0 °C affords N-aryl-(3S)-3-benzyloxypyrrolidine with a chemical purity typically ≥98.5% (GC-FID) and an enantiomeric excess of ≥99.5% (chiral HPLC, Chiralpak IA, n-hexane:ethanol 90:10 v/v, flow rate 1.0 mL/min, detection at 254 nm). The resulting chiral aryl intermediate is progressed to dopamine D3 receptor antagonists disclosed in AbbVie and Pfizer clinical portfolios; one representative series described in WO 2014/195432 achieves sub-nanomolar D3 binding affinities (Ki < 1 nM) and functional selectivity over D2 measured in a [³⁵S]GTPγS binding assay. The precise spatial projection of the benzyloxy group, fixed by the (S)-configuration, is determinative for D3 receptor subtype selectivity.

From a regulatory standpoint, intermediates destined for Phase II clinical trial supply must conform to ICH Q7 guidelines for section 19 (APIs for Clinical Trials). The starting chiron (3S)-3-benzyloxypyrrolidine hydrochloride is subjected to an ICH M7-compliant mutagenic impurity risk assessment. Trace benzyl chloride, a potential DNA-reactive agent formed during the benzylation step, is controlled to a limit of 10 ppm via a validated GC-MS method (single-ion monitoring, LOD 0.5 ppm). Residual palladium, heavy metals (USP <232>, ICP-MS), and residual solvents (ICH Q3C, Class 2) are monitored in each batch before release for GMP coupling.

Sigma-1 Receptor Ligands and the Requirement for Non-Coordinating Solvents

This chiral benzyloxypyrrolidine building block acts as the amine nucleophile in SNAr reactions with 2- or 4-halopyridines and haloimidazoles to construct sigma-1 receptor ligands. The hydrochloride salt is neutralized in situ with a tertiary amine—typically triethylamine (2.0–2.5 eq)—in anhydrous acetonitrile at 0–5 °C before the slow addition of the heteroaryl halide (1.0 eq). Non-coordinating solvents are mandatory; the use of DMF or DMSO promotes halide exchange and retards the SNAr rate, extending reaction times beyond 72 h and elevating the des-benzyl impurity above 2.5%. In acetonitrile at reflux (81–82 °C), full conversion is typically achieved within 12–18 h, and the product is isolated by aqueous workup and crystallization from ethyl acetate/n-heptane. The terminal sigma-1 pharmacophores derived from this intermediate have been optimized for pain and neuroinflammatory indications; described representatives in patent EP 2 883 871 B1 exhibit Ki values at σ1 receptors of 0.8–25 nM with > 50-fold selectivity over σ2.

Compliance requirements for sigma-1 receptor ligand production in preclinical and first-in-human batches emphasise controlled substance precursor handling because certain N-arylpyrrolidine derivatives fall under analog acts in jurisdictions such as the United States (Controlled Substances Act, schedule IV derivatives) and China (Catalog of Precursor Chemicals). Export control classification is determined by the exact final product structure, not the intermediate itself; however, when the (3S)-3-benzyloxypyrrolidine hydrochloride is shipped to contract manufacturing organizations (CMOs) in the EU, it is accompanied by a statement of non-narcotic use under Article 12 of Regulation (EC) No 273/2004. Environmental discharge limits for the benzyloxypyrrolidine derivative must comply with local Predicted No-Effect Concentration (PNEC) values; the octanol-water partition coefficient (log P 1.9 ± 0.3) indicates moderate bioaccumulation potential, and waste streams are treated with alkaline hydrolysis at 80 °C for 4 h to degrade the pyrrolidine ring before biotreatment.

Hydrogenolytic cleavage of the O-benzyl protecting group in (3S)-3-benzyloxypyrrolidine hydrochloride represents the dominant route to the corresponding (S)-3-hydroxypyrrolidine, a versatile intermediate for histamine H3 receptor inverse agonists. The salt is first converted to the free amine by partitioning with sodium carbonate solution and extracted into ethanol; ethanolic solutions are charged into a pressure-rated hydrogenation vessel equipped with a hollow-shaft gas-entrainment impeller. 10% w/w palladium on carbon ( 50% water-wet, 5 mol% Pd relative to substrate) is added, and the reactor is purged three times with nitrogen followed by hydrogen. Hydrogenation proceeds at 3–5 bar gauge pressure and 35–40 °C with vigorous agitation (800–1000 rpm) to overcome mass-transfer limitations. A temperature rise above 45 °C initiates pyrrolidine ring hydrogenolysis, generating N-ethyl and ring-opened byproducts that total 0.8–2.0% by GC. Reaction completion is monitored by the cessation of hydrogen uptake and by TLC (silica gel, ethyl acetate/methanol 9:1, ninhydrin stain).

Following catalyst filtration through a 0.2 μm polypropylene filter under nitrogen pressure, the filtrate is acidified with hydrochloric acid in isopropanol to precipitate (S)-3-hydroxypyrrolidine hydrochloride directly. The reductive debenzylation step is exothermic; in batch sizes exceeding 50 kg, incremental substrate addition over 60 min is practiced to limit the adiabatic temperature rise to 8 °C. The hydroxyl intermediate is then O-sulfonylated with p-toluenesulfonyl chloride (1.1 eq) in dichloromethane at 0–10 °C using triethylamine as base, and subsequently displaced with appropriate H3 pharmacophore amines to produce H3 receptor inverse agonists/antagonists such as pitolisant analogues containing a (3S)-aminopyrrolidine core. The entire synthetic sequence is validated under ICH Q11 for starting material designation, with the (3S)-3-benzyloxypyrrolidine hydrochloride designated as a regulatory starting material when its impurity profile (specified for (R)-enantiomer <0.3%, benzyl alcohol <0.15%, and total unknowns <0.5%) is controlled through a retest period of 24 months at 2–8 °C.

When Amide Bond Formation Competes with Racemization in mGluR5 Modulator Couplings

Carboxylic acid derivatives of the (3S)-3-benzyloxypyrrolidine scaffold are frequently coupled to aromatic amines in the synthesis of negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGluR5). The acid partner is prepared by N-alkylation with an ω-bromoalkanoate ester, saponification to the free acid with lithium hydroxide in THF/water at 0 °C, and acidification without exceeding pH 3.5 to avoid benzyl ether cleavage. Racemization at the C-3 center is a documented risk during activation of the carboxylic acid to the acid chloride; the use of oxalyl chloride with catalytic DMF in dichloromethane at −10 to −5 °C generates a mixed anhydride intermediate that maintains the enantiomeric ratio. In contrast, attempts to form the corresponding acyl imidazolide using CDI at 25 °C resulted in up to 12% racemization over 4 h, as determined by chiral HPLC analysis (Chiralcel OD-RH, phosphate buffer pH 2.5/acetonitrile).

Process robustness was established by coupling the pre-formed acid chloride with substituted anilines (1.05 eq) in the presence of N-methylmorpholine (2.5 eq) in anhydrous ethyl acetate at 0–5 °C. The amide product precipitates upon addition of n-heptane and is recrystallized from ethyl acetate/cyclohexane to afford ≥99.0% ee. These chiral amides are advanced to mGluR5 NAMs that have been profiled in preclinical models of fragile X syndrome and levodopa-induced dyskinesia; representative candidates reach brain-to-plasma ratios of 0.6–1.2 after oral dosing at 10 mg/kg in rodents, consistent with the moderate P-glycoprotein efflux ratio (1.8–2.3) measured in MDR1-MDCK assays. Compliance documentation for shipment to EU-based finishing sites includes a full material traceability report conforming to EU GMP Part II, and the amide intermediate is tested against a monograph derived from the Ph. Eur. general method 2.2.24 (sulfated ash) and 2.4.8 (heavy metals). The certificate of analysis additionally reports a specific optical rotation of the free base intermediate, [α]²⁵D +18.5° (c=1.0, MeOH), as an identity marker.

Chiral quaternary ammonium salts derived from (3S)-3-benzyloxypyrrolidine have been employed as phase-transfer catalysts (PTCs) for the asymmetric alkylation of glycine Schiff bases, a key transformation in the synthesis of unnatural amino acids. The quaternization is straightforward: the free base is alkylated with benzyl bromide (1.2 eq) in acetonitrile at 60 °C for 16 h, and the resulting hygroscopic ammonium bromide is recrystallized from acetonitrile/diethyl ether. The catalyst loading in a typical PTC glycine benzophenone imine alkylation ranges from 5 to 10 mol%, employing powdered potassium hydroxide (10 eq) as the base in toluene at −20 °C. Enantioselectivities of 85–94% ee have been reported for benzylation, with the (3S)-configuration of the catalyst directing facial selectivity. This application falls outside pharmaceutical GMP territory but is subject to industrial chemical regulations such as REACH (EC) No 1907/2006; the quaternary ammonium substance requires a registration dossier when manufactured or imported at ≥ 1 tonne/year. Toxicological screening under Annex VII of REACH includes an in vitro Ames test (OECD 471) and acute oral toxicity (OECD 423). For export, the Safety Data Sheet classifies the catalyst under GHS07 (exclamation mark) with H315/H319/H335 hazard statements, and it is packed in UN-approved 4G fiberboard boxes with inner LDPE liners meeting the test requirements of ADR 6.1.

Supply Chain Integrity for a Phase II 5-HT1A Agonist: KSM Specification Tightening

Clinical supply chains targeting serotonin 5-HT1A receptor partial agonists have adopted (3S)-3-benzyloxypyrrolidine hydrochloride as a registered key starting material (KSM). The decision to designate this chiral salt as a KSM under ICH Q11 relies on a demonstrated control strategy for the (R)-enantiomer, which, if carried through to the active pharmaceutical ingredient, acts as a potent ligand at off-target serotonin subtypes. The KSM specification enforces a chiral purity of ≥99.7% ee (chiral SFC, Chiralpak AD-H, CO₂/MeOH 85:15, backpressure 120 bar) and a limit for the debenzylated impurity (3S)-3-hydroxypyrrolidine at <0.10%. Each batch is subjected to an ICH Q3A quantitative threshold assessment; any unidentified impurity present at >0.10% triggers structural elucidation by LC-HRMS and NMR before acceptance.

The terminal 5-HT1A agonist API, whose structure embeds the benzyloxypyrrolidine as a hinge-region binding motif, is formulated as a hydrochloride salt with a pKa of 8.9 and an aqueous solubility of >5 mg/mL at physiological pH. In the final API step, the benzyl group is retained to achieve slow dissociation kinetics from the receptor, which pharmacological studies associate with an extended half-life of receptor occupancy (>12 h in PET imaging). GMP synthesis of the KSM on multikilogram scale uses ethanol/water (95:5) recrystallization and jet milling to achieve a consistent particle size D90 of <150 µm, a parameter critical for dissolution performance of the subsequent BOC-protected intermediate during processing in a 500 L glass-lined reactor. Storage stability data over 36 months at controlled room temperature (25 °C/60% RH) show no increase in total impurities beyond the acceptance criterion of 0.5%, confirming the suitability of the material for long-term stockpiling in geographically distributed clinical supply chains. The certificate of analysis will additionally reference compliance with Ph. Eur. method 2.5.12 (water: semi-micro determination) and USP <231> for heavy metals in pharmaceutical precursors.